Kazia Therapeutics Ltd ADR

Stock Chart, Company Information, and Scan Results

$12.26(as of Apr 24, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Kazia Therapeutics Ltd ADR Company Information, Fundamentals, and Technical Indicators

Stock Price$12.26
Ticker SymbolKZIA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees6
CountyUSA
Market Cap$140.1M
EBIDTA-17.8M
10-Day Moving Average10.68
P/E Ratio-0.75
20-Day Moving Average9.36
Forward P/E Ratio12.82
50-Day Moving Average8.21
Earnings per Share-7.61
200-Day Moving Average8.12
Profit Margin-Infinity%
RSI73.60
Shares Outstanding11.4M
ATR1.11
52-Week High17.40
Volume225,400
52-Week Low3.05
Most Recent Support Level9.85
Book Value46.4M
Most Recent Resistance Level11.75
P/B Ratio0.82
Upper Keltner11.86
P/S Ratio15.16
Lower Keltner6.86
Debt-to-Equity Ratio11.86
Next Earnings DateUnknown
Cash Surplus45.0M
Next Ex-Dividend DateUnknown

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Kazia Therapeutics Ltd ADR In Our Stock Scanner

As of Apr 27, 2026
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.